Exosome Diagnostics, Inc. services

Cells from healthy and diseased tissues shed billions of exosomes into the blood and other biofluids; the resulting total exosome content is the accumulation of exosomes contributed from all tissue. Only a fraction of these exosomes are  derived from a specific cell or tissue type.

After marker identification, biomarkers and/or gene signatures enter our development process to become targeted assays.  The newly identified biomarkers are developed into a Laboratory Developed Test (LDT) that will be run in Exosome Diagnostic’s CLIA and CAP accredited laboratory.